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ABSTRACT  
Purpose: Africa has low breast cancer incidence rates, but high mortality rates from this disease due to poor survival. 
Delays in presentation and diagnosis are major determinants of breast cancer survival but these have not been 
comprehensively investigated in Africa. 
Methods: MEDLINE, Embase and Global Health were searched to identify studies reporting on delays in presentation 
and/or diagnosis of breast cancer published between 01/01/2000 and 31/05/2016. Data were synthesised in narrative, 
tabular and graphical forms. Meta-analyses were not possible due to between-study differences in the way delays were 
reported.   
Results: 21 studies were included in the review. Study-specific average times between symptom recognition and 
presentation to a health care provider ranged from <1 to 4 months in North Africa and from <3 to >6 months in Sub-
Saharan Africa (SSA). Study-specific average times from presentation to diagnosis were <1 month in North Africa, but 
ranged from <3 to >6 months in SSA. Reported reasons for these delays included patient-mediated (e.g. socio-
economic factors) and health system-mediated factors (e.g. referral pathways). 
Conclusions: This systematic review revealed marked delays in presentation and diagnosis of breast cancer in Africa. 
Identification of their drivers is crucial to the development of appropriate control strategies in the continent. 
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ABBREVIATIONS  
BC: breast cancer 
BSE: breast self-examination 
CBE: clinical breast examination 
CI: confidence interval 
HCP: health care provider 
HICs: high-income countries  
HIV: human immunodeficiency virus  
IDC: invasive ductal carcinoma 
IQR: inter-quartile range 
LABC: Locally advanced breast cancer 
LMICs: low- and middle-income countries 
Md: median 
Me: mean 
mths: months 
n/a: not applicable as not reported in the original publication  
OR: odds ratio  
Ra: range 
SD: standard deviation 
SSA: Sub-Saharan Africa 
wks: weeks 
wMe: weighted mean 
yrs: years 
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INTRODUCTION  
Women in Africa currently have one of the lowest incidence rates of breast cancer worldwide (1). However, the burden 
from this cancer is expected to increase markedly in the next decades. A growing aging population alone, i.e. assuming 
incidence rates will remain constant, will lead to an estimated 119,918 new cases in 2030, a near doubling in the 
number of incident cases over 20 years (2). The increase will be even more marked as incidence rates are likely to rise 
due to the adoption by African women of more westernized lifestyle profiles, particularly reproductive patterns 
characterised by late age at first full-term pregnancy, lower parity, reduced lifetime breastfeeding duration as well as 
increases in postmenopausal weight (3). 
Despite breast cancer incidence rates being still relatively low in Africa, mortality rates from this disease are 
as high, or higher, than in high incidence countries due to poor survival (1). Furthermore, the proportion of breast 
cancer cases and deaths at premenopausal ages is higher in Africa than in high-income countries (HICs), where disease 
incidence is highest, reflecting the younger age structure of the continent’s population and possibly also distinctive risk 
factors and/or tumour characteristics. Consequently, breast cancer in Africa disproportionately affects women in the 
prime of their lives and hence it has particularly marked familial, societal and economic consequences. 
A recent systematic review (4) shows that a high proportion of breast cancer patients in sub-Saharan Africa 
(SSA) are diagnosed with late-stage disease leading to poor survival (5). Studies from HICs have shown that delays 
between onset of symptoms and start of treatment are main determinants of late-stage presentation and poor survival 
(6). Previous studies have attempted to examine delays in breast cancer presentation, diagnosis and treatment in Africa 
(5,7) but, to our knowledge, these have not been comprehensively investigated across the continent. Knowledge of the 
length of time intervals between symptom recognition, presentation, diagnosis and start of treatment – and of the 
factors that may influence them – is key to the development of strategies to shorten them. Therefore, we conducted a 
systematic review to investigate delays in presentation and diagnosis of breast cancer in Africa, and their determinants. 
 
MATERIAL AND METHODS  
Conceptual framework 
Figure 1 depicts a patient’s trajectory from the moment she first notices symptom(s) to the time when treatment starts 
as well as the factors that may affect her journey. In HICs with free universal access to health care the delay from a 
woman first noticing potential symptoms of breast cancer to her presentation to a health care provider is labelled as 
“patient delay” as it is essentially driven by patient-mediated factors. In contrast, the time from first medical 
consultation to the beginning of definitive treatment is labelled as “provider delay” as it is driven predominantly by 
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health system-mediated factors. However, in many African settings the picture is likely to be far more complex as 
delays in both presentation and diagnosis are likely to result from a complex interplay between patient-mediated and 
health system-mediated factors. For instance, a woman may delay presentation not only because of her lack of breast 
cancer awareness but also because of the unavailability of health care providers in her area of residence. Similarly, a 
woman who first presents with a suspicious cancer may delay diagnosis due to fear of its consequences (e.g. 
mastectomy, death). In this review, we will consider presentation delays as the time interval from symptom 
recognition to presentation to the first health care provider, diagnostic delays as the time interval between presentation 
and breast cancer diagnosis, and treatment delays as the time interval between diagnosis and start of cancer treatment. 
These terms do not carry any judgement on whether these delays are primarily induced by patient-mediated or 
provider-mediated factors.  
 
Search methodology 
The PRISMA statement guidelines (8) were followed to select relevant publications on delays in breast cancer 
presentation and diagnosis in Africa. Papers were eligible for inclusion in the systematic review if they reported 
findings from primary research studies conducted in Africa; reported on delays in presentation and/or diagnosis of 
female breast cancer patients; and were published between the 1st January 2000 and the 31st May 2016. No language 
restrictions were imposed. Relevant publications were searched in the electronic databases MEDLINE, Embase, and 
Global Health. A search strategy using synonyms (including truncations) and subject headings of the search concepts 
“breast cancer”, “late diagnosis”, “Africa” and “determinants”, and the Boolean operators “AND” and “OR” was used 
(Appendix A). All titles and abstracts were screened to identify potentially eligible papers and the full-text for these 
retrieved and critically reviewed to assess eligibility and, if eligible, to extract relevant data.  
 
Data extraction 
The data extraction from each eligible paper was carried out independently by two reviewers (CE and IdSS) using a 
specifically developed standardised data extraction form. The following information was extracted: the type of 
catchment population (e.g. country; urban, rural or mixed); the study design (quantitative, qualitative, mixed); the type 
of recruitment source (primary, secondary or tertiary hospital/clinic) and approach (eligibility criteria; recruitment 
period; type of sample: consecutive or convenience, i.e. opportunistic; sample size); patient (e.g. age) and tumour 
characteristics (e.g. stage, size, histology, symptoms); source (e.g. patient, medical records) and timing of collection 
(e.g. prior or after diagnosis) of data on delays and their reasons; reported times between symptom recognition, 
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presentation, diagnosis and start of treatment; and patient-mediated and health system-mediated factors that might have 
influenced them. Disagreements between the two reviewers were discussed and a consensus reached.  
 
Quality assessment of the eligible papers 
The quality of the articles included in the review was assessed independently by the same two reviewers. A 
standardized quality assessment form was developed which included parameters to assess the potential for selection 
and information bias as well as the appropriateness of the analytical methods used, including those for dealing with 
potential confounders (Appendix B). The overall quality score of a paper was expressed as the sum of its parameter-
specific scores, which could range from 0 (lowest) to 30 (highest). The higher the score, the higher the methodological 
quality of the paper; the lower the score, the more likely its findings might have been affected by biases.  
 
Data synthesis 
Data were synthesised in narrative, tabular and graphical forms. Study-specific mean (SD), or median (range), 
presentation, diagnosis and treatment delays are presented; if only categorical data were reported in the original 
publication we used them to estimate the median, or a weighted mean, whenever possible. Studies differ greatly in the 
way they obtained information on potential reasons for delays and in the way such data were presented (Appendix C). 
Most studies simply presented data in a descriptive way (e.g. percentages), but a few used logistic regression methods 
to estimate crude and/or adjusted odds ratios (OR) for delayed presentation, diagnosis or treatment for each variable 
examined, with studies using different cut-off points to define such delays (e.g. from ≥2.2 to >6 months for delay in 
presentation and from >2 weeks to ≥6 months for delays in diagnosis; Appendix C). One study in North Africa (9) 
reported on delays but only examined factors associated with late (III/IV) versus early stage at diagnosis; late stage was 
taken here as a proxy for delays between symptom recognition and diagnosis. Findings are shown separately for 
studies conducted in North Africa (i.e. in Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, and Western Sahara) and 
sub-Saharan Africa (SSA, i.e. countries in East, Middle, South and West Africa) as defined by the United Nations (10).  
 
RESULTS 
A total of 315 papers (after removal of duplicates) were identified through electronic searches and their titles and 
abstracts screened for potential eligibility (Figure 2). In all, 35 articles were retrieved for full-text review. Of these, 
only 21 were eligible for inclusion in the review: 16 quantitative studies, three qualitative studies and two mixed 
(quantitative and qualitative).  
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Study characteristics 
Table 1 summarizes the main characteristics of each participating study. Of the 18 quantitative and mixed design 
studies, eight (44%) were conducted in North Africa and ten (56%) in SSA, with their sample sizes ranging from 44 to 
350. In contrast, all three qualitative studies were conducted in SSA, with sample sizes ranging from 9 to 31. All 
studies were hospital-based cross-sectional surveys that relied on consecutive samples of patients, except for two small 
qualitative studies (11,12) which relied on convenience samples. Eligibility was restricted to women with advanced 
breast cancer in one study in North Africa (13) and in four (three quantitative (14-16) and one qualitative (11)) in SSA. 
The large majority recruited breast cancer patients diagnosed predominantly in the years 2000-2010, but two studies in 
North Africa (17,18) and two in SSA (19,20) included patients diagnosed after 2010 whereas one study in SSA 
recruited patients diagnosed prior to 2000 (21) (Table 1). The average (mean/median) age at breast cancer diagnosis 
was in the 40s in the large majority of studies. Most studies involved collection of data through structured or semi-
structured questionnaires, usually administered by the researchers or medical staff around the time of diagnosis, but 
four were conducted retrospectively using medical records (14,15,17,22). Information on ethnicity was provided in 
only one study, which stated that its subjects were all Black (12). Information on tumour stage at diagnosis was 
available for seven (88%) studies in North Africa and nine (69%) in SSA. Among studies with stage information, and 
whose subject eligibility was not dependent on it, the proportion of patients with late stage (III/IV) was very high 
(range: 46%-61% in North Africa; 76%-91% in SSA; Table 1).  
Quality scores were low for most quantitative studies (Table 1) albeit slightly higher for those from North 
Africa (median=18.5; range: 14-25) than for those from SSA (median=17.5; range: 7-25). Similarly, the quality of the 
qualitative and mixed design studies varied substantially, with three studies presenting more in-depth qualitative results 
(12,20,23). 
 
Delays in presentation and diagnosis  
The time interval between symptom recognition by the woman to presentation, i.e. to first visit to a health care 
provider, varied substantially across studies but, overall, it was shorter in North Africa than in SSA (Table 2; Figure 
3a). Of the five North African studies that reported on presentation delays, most yielded median estimates of <2.5 
months; the only exception was a study in Libya (24) with a median presentation time of 4 months. Of the five studies 
in SSA that provided estimates of time from symptom recognition to presentation only one (25) reported a median time 
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of <2.5 months, with the remaining reporting average times ranging from 3.4 months in Mali (21) to >6 months in 
South Africa (15). 
Fewer studies in North Africa (18,24,26) and in SSA (19,25,27) gave estimates of the time between 
presentation and diagnosis, or between diagnosis and start of treatment. Nevertheless, the length of these intervals 
tended to be shorter than the length of the corresponding intervals between symptom recognition and presentation in 
North Africa (all <1 month), but not in SSA (Figure 3b).  
Five North African studies provided median estimates of the total delay from symptom recognition to date of 
breast cancer diagnosis or start of treatment (Figure 3c). Two of these studies recruited only advanced breast cancer 
cases with average total delays of 8 (13) and 12 months (14). Median estimates of the total delay from symptom 
recognition to diagnosis for the remaining three studies ranged from 4 (18) to 8.5 months (17). Five SSA studies 
provided average times from presentation to diagnosis or start of treatment (Figure 3c), with their estimates ranging 
from 7.9 months in Ghana (28) to 15 months in Rwanda (19); median delays were known to be >6 months for two 
studies (25,27) but their exact values could not be estimated. In addition, a small qualitative study (n=11) in Botswana 
reported a median time from first symptom(s) to presentation at the hospital where the diagnosis was finally made of 3 
years (12).  
 The number of health care providers visited prior to the one where the diagnosis was made were reported by 
only one study in North Africa (26) and four in SSA (19,21,23,27), with estimates ranging from a median of 1.5 in 
Egypt (26) to >5 in Rwanda (19); however, these estimates are not entirely comparable because traditional and 
religious healers were included in two of these studies (23,27).  
A few studies examined whether delays were associated with late stage (III/IV) at diagnosis. The study by 
Benbakhta et al. (18) in Morocco reported a 6.81-fold (95% CI: 3.65, 12.7) increase in the odds of late stage among 
patients who delayed presentation by >64 days relative to those who presented ≤64 days of symptom recognition. 
Similarly, the odds of late stage among patients who experienced a diagnostic delay of ≥50 days was 1.84 (95% CI: 
1.05, 3.23) times higher than among those diagnosed <49 days of their first presentation to a health care provider (18). 
The study by Mousa et al. (26) in Egypt also reported an association between late stage and delays in presentation >3 
months (crude OR: 1.99; 95% CI: 1.01, 1.99), but not with delays in diagnosis >2 weeks. In Rwanda, late stage was 
positively associated with both presentation (median (range) in months: 2 (1-12) for stages I/II, 5 (1-13) for stage III 
and 9 (3-18) for stage IV; p=0.09) and diagnostic delays (4 (2-13) months for stage I/II, 4 (2-10) for stage III and 11 
(5-28) for stage IV; p=0.005) (19). 
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Factors associated with delays  
Appendix C summarises the reasons most commonly reported by the quantitative studies in the review for late 
presentation to the first health care provider. They fell into the following categories: (i) socio-economic factors such as 
low educational level; (ii) lack of breast cancer awareness and poor knowledge of early-detection methods (e.g. breast 
self-examination); (iii) type of initial symptoms: painless, not taken seriously or hoping they would resolve soon; (iv) 
fear of the disease, its treatment (e.g. mastectomy) or death, or of being a burden to the family; (v) belief in traditional 
medicine or spiritual cures; (vi) financial constraints; and (vii) poor access to health care (e.g. living too far away from 
a health care provider; lack of transportation). Benbakhta et al. (18) found in mutually-adjusted analysis that a delay in 
presentation of ≥2.2 months in Morocco was positively associated with low socio-economic conditions (e.g. living in a 
rural area, being illiterate, being a housewife (vs. being employed) and having low socio-economic level) and lack of 
breast cancer awareness (e.g. negative family history of cancer, no knowledge of breast self-examination) (Appendix 
C). In contrast, Mousa et al. (26) found no association between delay in presentation >3 months in Egypt and a 
woman’s socio-economic characteristics or type of symptoms before or after adjustment for potential confounders. In 
South Africa, Marcus et al. (15) found in mutually-adjusted analysis positive associations with late presentation (>6 vs. 
3-6 months) with increasing age and a previous cancer diagnosis, but not with educational level, marital status or being 
employed/unemployed. A mutually-adjusted analysis of data from a study in Rwanda (19) revealed a four to five-fold 
increase in the odds of late presentation (≥6 months) for patients with low or no education, and for those who visited a 
traditional healer first, but no independent associations with other socio-economic, breast cancer awareness, symptom 
or health services-related variables (Appendix C). Overall, the findings from the qualitative studies supported the 
evidence from the quantitative studies (11,12,20,23) (Appendix C). 
 The reasons given by the patients for delays between presentation and diagnosis, or start of treatment, 
included patient-mediated factors (e.g. socio-economic factors, type of symptoms, having tried traditional treatments 
first, financial problems, fear of the disease and/or its treatment, and denial) as well as health care provider-mediated 
factors (e.g. travel time to health care provider, the number and type of health care providers contacted prior to 
diagnosis, delayed referrals or non-referrals, misdiagnosis, wrong advice or false reassurances, delays in obtaining 
diagnostic confirmation and in starting treatment) (Appendix C). The study in Morocco by Benbakhta et al. (18) found 
in mutually-adjusted analyses that a delay >1.7 months between presentation and start of treatment was associated with 
older age, illiteracy, low socio-economic level, distance to health care provider ≥100 kms and ≥3 consultations prior to 
the diagnostic one. Mousa et al. (26) in Egypt showed that after adjustment for potential confounders the odds of a 
delay >2 weeks from the first medical consultation to arrival at the diagnostic centre was not associated with the 
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patient’s age, socio-economic conditions or type of  symptoms but was strongly associated with the type of the first 
health care provider visited and the navigation pathway followed by the patient (Appendix C). In Rwanda, Pace et al. 
(19) found in mutually-adjusted analyses a 2.69 (95% CI 1.24, 5.84) higher odds of a delay ≥6 months  for patients 
who visited five or more health care facilities prior to diagnosis, but no associations with the patient’s socioeconomic 
conditions, reproductive history or type of symptoms. In the qualitative studies (Appendix C), some women reported 
poor clinical practices (e.g. inadequate diagnosis by general doctors (11)), hospital strikes (20), or having sought 
alternative care after receiving the diagnosis). 
 
DISCUSSION 
To our knowledge, this is the first systematic review of studies that reported on delays in a woman’s breast cancer 
journey in Africa. Its findings highlighted three main issues. Firstly, there is a paucity of published data on delays in 
the presentation and diagnosis of the most common female cancer in Africa (2). The systematic review identified only 
21 published studies over the 16-year period (January 2000-May 2016), comprising only 2,788 breast cancer patients 
from across the continent (1,382 from North Africa; 1,406 from SSA). Secondly, the findings revealed marked delays 
in presentation and diagnosis of breast cancer patients in both North Africa and SSA. Thirdly, the reported reasons for 
such delays were complex and included both patient-mediated and health system-mediated factors; however, the 
relative importance of these two types of factors varied from setting to setting.  
There is strong evidence that a delay from symptom recognition to diagnosis of more than three months is 
associated with later stage at presentation and poorer survival (6). This review revealed substantially longer delays in 
both North Africa and SSA, with reported average times from symptoms recognition to diagnosis between 4 and 15 
months. These estimates are in line with those observed in other low and middle income countries (LMICs) (e.g. 7.6 
months in Brazil (29); 5.5 months in Malaysia (30)) but much higher than those observed in HICs (e.g. 34 days in 
France (31); 48 days in the USA (32)). The very long time intervals from symptom recognition to diagnosis in Africa 
resulted from delays in both presentation and diagnosis. All studies in this review, with the exception of two (9,33), 
reported average presentation intervals between 2.2 months and >6 months, much longer that those observed in HICs 
(e.g. 9 days in the United Kingdom (34); 16 days in Germany (35)). Similarly, reported diagnostic intervals in Africa 
were much longer than those found in HICs (e.g. from 10 to 42 days in France (31), Germany (36) and the USA (32)), 
but similar to what has been described for other LMICs (e.g. median of 5 months in Brazil (29), Colombia (37) and 
Mexico (38)). 
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As we had hypothesized in our conceptual model, delays in presentation in Africa were found to be associated 
not only with patient-mediated factors (e.g. low educational level, poor breast cancer awareness, use of alternative care 
medicine) but also with health services-mediated factors (e.g. distance to the nearest health care centre). These results 
are similar to those from previous studies – e.g. being unaware of the warning signs or tests for breast cancer (5), 
patients only seeking conventional care when traditional treatment has failed (39), or inability to afford the costs of 
treatment (40). Similarly, delays in diagnosis in Africa were influenced by both patient-mediated factors (e.g. low 
educational level, financial problems) and health system-mediated factors (e.g. type of first health care provider 
visited, number of providers visited prior to diagnosis, type of navigation pathway followed before reaching the 
diagnostic centre). A high number of referrals makes the patient’s journey through the health system longer resulting in 
a more advanced tumour stage at diagnosis; however, it is also conceivable that a low number of referrals might reflect 
a more aggressive tumour, or a longer time interval before presentation to the first health care provider, and thus a 
more advanced tumour that was easily identified by the physician. Of note, however, is the fact none of the papers 
directly examined health system factors, e.g. through interviews with health care providers, relying instead on patients’ 
reports.    
 
Strengths and limitations of the review 
Major strengths of this review include the systematic search strategy used to identify eligible English and non-English 
publications, and the use of standardised methods for data extraction and synthesis. The review also has weaknesses. 
Its representativeness may have been compromised by several factors. First, publication bias cannot be excluded as 
grey literature was not included in this review. Second, the review included studies from only 4 of the 7 North African 
countries and 11 of 51 SSA countries, albeit the latter comprised studies from all four SSA regions (i.e. from Eastern, 
Western, Southern and Middle Africa). Third, none of the studies in the review were population-based; they were all 
hospital-based, predominantly from tertiary hospitals as these are the only ones in most African countries to have 
appropriate cancer diagnostic and treatment facilities. However, such studies excluded, by design, the large number of 
patients who never reach tertiary hospitals, some of whom are never diagnosed. Hence, the included patients who 
reached tertiary facilities are unlikely to be a representative sample of all breast cancer patients in Africa.  
The methodological quality of most papers was low. In particular, measurement errors may have affected the 
validity of the review’s findings as although most of the studies recruited women prospectively, patients were asked to 
remember the time from first symptom(s) to presentation, and this might have introduced recall errors, and even biases. 
Little detail was provided in the original papers on the specific instruments used to collect information and the methods 
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used to estimate times to presentation, diagnosis and treatment, including on the way questions to patients on time 
intervals were formulated and on how relevant time-related events (e.g. dates of contact with a first health care 
provider, breast cancer diagnosis and start of treatment) were defined. Between-study differences in these 
methodological issues may have affected their comparability. When questioned about the reasons for delays patients 
might have been reluctant to admit less orthodox behaviours such as the use of traditional medicine. Reassuringly, 
however, the studies that examined associations between self-reported delays and late stage at diagnosis showed, as 
expected, strong positive associations. Many studies had relatively small sample sizes and thus their ability to precisely 
quantify delays, and their power to detect associations, were limited. There were large variations across studies in the 
way data were analysed (e.g. only a few quantitative studies attempted to control for confounders; none of the 
qualitative studies conducted theoretical analyses), and summary findings presented, hampering between-study 
comparisons and precluding the conduct of meta-analyses.  
 
CONCLUSIONS 
Several studies in Africa have shown that early stage breast cancer is associated with better survival than late stage 
disease (41,42), consistent with early diagnosis and treatment being associated with reductions in mortality from this 
disease in the region. The long presentation and diagnostic delays identified by this review indicates that there is 
considerable potential to introduce interventions aimed at shrinking the time intervals between symptom recognition 
and diagnosis. Mammography screening is often advocated as the best intervention to improving early diagnosis of 
breast cancer but the findings from this review strongly argue against adopting such an approach in African settings. 
Screening can only reduce breast cancer mortality if women with suspicious screen-detected lesions have access to 
appropriate diagnosis and treatment. Despite the limitations of the existing data, and the high heterogeneity across 
African settings, the long diagnostic delays highlighted by the review indicate that the addition of women with 
asymptomatic screen-detected tumours would place significant additional burden on most, already over-stretched, 
healthcare systems in the region. Instead, downward stage migration of symptomatic breast cancer should be the 
priority in most settings as recommended by the Breast Health Global Initiative and the Breast Cancer Initiative 2.5 
(43). To achieve this would require increased breast cancer awareness of the population, enhanced ability of primary 
and secondary health care professionals to diagnose breast cancer as well as clear patient navigation pathways to 
facilitate timely referral and admission of patients to tertiary care services for early care. The introduction of such an 
approach in other LMICs has demonstrated that downward stage migration of breast cancer is achievable in the 
absence of screening (44).   
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Table 1: Main characteristics of the 21 studies included in the review 
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r
 
[
r
e
f
 
n
o
]
 
C
o
u
n
t
r
y
 
 
(
s
a
m
p
l
e
 
s
i
z
e
)
 
Hospital/clinic, 
location 
H
o
s
p
i
t
a
l
/
c
l
i
n
i
c
-
b
a
s
e
d
 
c
a
t
c
h
m
e
n
t
 
p
o
p
u
l
a
t
i
o
n
a
 
Recruitment 
Eligibility criteria Age (yrs) 
Tumour characteristics 
Total 
quality 
score 
(max. 
score=30) 
T
y
p
e
 
o
f
 
h
o
s
p
i
t
a
l
/
c
l
i
n
i
c
b
 
T
y
p
e
 
o
f
 
s
a
m
p
l
e
c
 
T
i
m
i
n
g
 
o
f
d
 
T
i
m
e
 
p
e
r
i
o
d
 
First symptom(s) Late stagee Size (cm) Grade 
ER status/ 
Histology 
QUANTITATIVE STUDIES (n=16)  
North Africa (n=8)  
A
h
m
e
d
,
 
2
0
1
4
 
 
(
1
4
)
 Sudan 
(n=141) 
National Cancer 
institute, Wad 
Medani city   
M  
 
(U: 
55.6
%; R: 
44.4
%) 
T C Re 
April 
2009 -
May 2010 
Locally advanced breast 
cancer (LABC) who 
attended the breast clinic  
Md: 46  
 
Ra: 25-71 
 
Me: 47 
n/a 
LABC 
(IIIA: 
13.2%; 
IIIB: 
78.5%; 
IIIC: 8.3%) 
n/a 
I: 2.1% 
II: 
20.1% 
III: 
77.8% 
ER+: 
70.1% 
IDC: 
77.1%  
14 
A
l
o
u
l
o
u
,
 
2
0
1
5
 
(
1
7
)
 Morocco 
(n=130) 
Department of 
radiotherapy, 
CHU Mohammed 
VI, Marrakech 
(public teaching 
hospital) 
n/a T  C Re Jan 2012 – Jan 2013 
Histologically confirmed 
breast cancer (BC)  
Me: 46 
 
Ra: 20-
78 
Lump: 58.5%;  
Ulceration: 16.2%;  
Metastasis: 13.8%; 
Inflammation: 
11.5% 
T2-T4: 
75% Mean
: 3.5  
II: 56% 
III: 
28% 
IDC: 90% 14 
B
e
n
b
a
k
h
t
a
,
 
2
0
1
5
 
(
1
8
)
 
Morocco 
(n=200) 
Department of 
radiotherapy, 
Institute National 
of Oncology, 
Rabat 
U: 
74% T C P 
Dec 2012-
May 2013 
Inclusion: All female 
patients with a BC 
diagnosis treated at this 
institution; Moroccan 
nationality; provided 
written consent.  
Exclusion: those who had 
started neo-adjuvant 
chemotherapy.   
Me ± SD: 
49.1 ± 
10.7 
 
Ra: 25-
82 
Breast lump: 46% III: 43%;  IV: 3% Mean
: 4.1 
n/a n/a 23 
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E
l
-
S
h
i
n
a
w
i
,
 
2
0
1
3
 
(
3
3
)
 Egypt 
(n=45) 
Ain Shams 
University (ASU) 
Hospital Breast 
Clinic 
M 
(Greate
r Cairo: 
63%) 
T  C P 
Feb 2010 
–  
Dec 2010 
Inclusion: Recently 
diagnosed BC patients (< 6 
mths).  
Exclusion: patients unaware 
of their disease, recurrence 
disease, poor general health 
(289 excluded)  
Md ± SD: 
47 + 10.2  
 
Me ± SD: 
48.2 + 
10.2 
Painless breast 
mass: 57.8%;  
painful breast 
mass: 15.6% 
n/a n/a n/a n/a 15 
E
r
m
i
a
h
,
 
2
0
1
2
 
(
2
4
)
 
Libya 
(n=200) 
African Oncology 
Institute (NOI), 
Sabratha 
n/a T  C P 
1 Jan 2008 
–  
31 Dec 
2009 
Female patients with BC 
diagnosed at NOI 
Me: 45.4  
 
Ra: 22-
75 
Lump: 68%; 
skin changes: 
15.5%; 
nipple discharge: 
13.5%;  
systemic: 3.0% 
III: 54%;  
IV: 11.5% 
T1 & 
T2 
(≤5 
cm): 
40%;  
T3 & 
T4: 
60%   
n/a n/a 19 
L
a
n
d
o
l
s
i
,
 
2
0
1
0
 
(
1
3
)
 
Tunisia 
(n=160) 
Dept Medical 
Oncology, Centre 
Hospitalier 
Universitaire 
Farhat Hached, 
Sousse 
M 
 
(U: 
37%; 
R: 63% 
) 
T C P 
1 Sept 
2005 - 31 
March 
2006 
Patients presenting with a 
locally advanced  (T3 or 
T4) or a metastatic breast 
cancer 
Me: 48  
 
Ra: 27-
85 
n/a 
T3: 25%; 
T4: 71%; 
M1: 24% 
Mean
: 6.3 
cm 
(rang
e: 3-
15 
cm) 
n/a n/a 18 
M
o
u
s
a
,
 
2
0
1
1
 
(
2
6
)
 
Egypt 
(n=163) 
Tanta Cancer 
Center (TCC), 
Gharbiah 
province (the 
largest cancer 
centre in the Nile 
delta region) 
M 
 
(U: 
36.8%; 
R: 63%) 
T  C P 
Dec 2009 
- Nov 
2010 
Newly diagnosed BC cases  
Md: 53  
 
Me ± 
SD: 
51.6+11.
5 
Mass: 77.4%; 
pain: 7.6%; 
nipple discharge: 
3.1%; 
increased breast 
size: 2.5%; 
axillary mass: 
2.5%;  
other: 6.9% 
III & IV: 
60.9% n/a 
n/a n/a 25 
S
t
a
p
l
e
t
o
n
,
 
2
0
1
1
 
[
(
9
)
]
 
Egypt 
(n=343) 
National Cancer 
Institute (NCI), 
Cairo (n=200) & 
Tanta Cancer 
Center (TCC), 
Gharbiah (n=143) 
M T  C P July 2007-Aug 2008 
Inclusion criteria: females 
with a newly diagnosed or 
treated BC between July 
2007 and August 2008 
recruited from 
chemotherapy outpatient 
clinics.  
Exclusion criteria: patients 
aged <18 yrs,  pregnant or 
lactating, previous cancer 
diagnosis 
Me ± SD: 
49.2 + 
10.9 
(early-
stage) 
 
 
Me ± 
SD: 49.9 
+ 11.0  
(late-
stage) 
n/a Late-stage: 46.1% n/a 
n/a n/a 23 
SUB-SAHARAN AFRICA (n=8) 
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C
l
e
g
g
-
L
a
m
p
t
e
y
,
 
2
0
0
9
 
(
2
8
)
 Ghana 
(n=66) 
Korle Bu 
Teaching 
Hospital 
n/a T  O P 
Sept 
2007-July 
2008 
Newly diagnosed breast 
cancer 
Md: 43  
 
Ra: 20-84 
 
Me: 44.8 
n/a n/a n/a n/a n/a 16 
E
z
e
o
m
e
,
 
2
0
1
0
 
(
2
5
)
 Nigeria 
(n=162) 
University of 
Nigeria Teaching 
Hospital Enugu 
(UNTH-E) 
n/a T C P 
June 1999 
- June 
2001 & 
April 
2003 -
May 2005 
Breast cancer patients 
managed at the Surgical 
Oncology unit at the 
UNTH-E who provided 
consent 
Md: 45  
 
Ra: 21-77 
 
Me: 45.7 
n/a III: 40.8%; IV: 37.5% n/a n/a n/a 23 
I
b
r
a
h
i
m
,
 
2
0
1
2
 
(
4
5
)
 
Nigeria 
(n=201) 
Lagos State 
University 
Teaching 
Hospital 
(LSUTH) 
 U T  C P Jan 2009 - Dec 2010 
All female BC patients 
referred to one of the 
general surgery out-patient 
clinics of LSUTH 
Mean: 
49.82 
(SD: 
13.59) 
 
Ra: 23-
104 
n/a III: 62.7%; IV: 16.4% n/a n/a n/a 23 
M
a
r
c
u
s
,
 
2
0
1
3
 
(
1
5
)
 
South 
Africa 
(n=103) 
Sebokeng 
Hospital, Gauteng  U 
Level 
2 
publi
c 
regio
nal 
hospi
tal 
C Re Jan 2007 - Dec 2010 
All patients presenting at 
the breast clinic with 
advanced BC (IIB or 
higher)  
Me: 59 
 
Ra: 34-83 
Breast lump: 
84.5%; axillary 
node abnormal: 
19.4%; 
abscess/ulcers: 
7.8%; nipple 
discharge: 6.8%; 
pain: 4.9% (not 
mutually 
exclusive) 
III-IV: 
95.1% n/a n/a n/a 13 
O
t
i
e
n
o
,
 
2
0
1
0
 
(
1
6
)
 
Kenya 
(n=166; 
98.8% 
females) 
Kenyatta 
National Hospital 
(KNH) 
M T C P 
1 Oct 
2003 – 31 
March 
2006 
Inclusion: all (male and 
female) patients who 
attended the breast clinic or 
were admitted to the three 
surgical wards with 
advanced BC (stages 
III/IV). Exclusions: patients 
with treated or recurrent BC  
Me: 47 
 
Ra: 17-
88 
Breast lump: 
87.3% 
III/IV: 
100% n/a n/a n/a 15 
M
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P
a
c
e
,
 
2
0
1
5
 
 
(
1
9
)
 Rwanda 
(n=144) 
Butaro and 
Rwinkwavu rural 
hospitals 
R 
S or 
T 
(n/a) 
C P Nov 2012 
- Feb 2014 
Inclusion: Women aged 
≥21 yrs with pathologically 
confirmed BC.  
Exclusions: women 
diagnosed elsewhere >6 
mths without initial staging   
Md: 49 Breast pain: 59% III: 52%;  IV: 24% n/a n/a n/a 25 
P
r
i
c
e
,
 
2
0
1
2
 
(
2
7
)
 Cameroon 
(n=50 BC 
cases; 
includes 
other 
cancers) 
Yaounde General 
Hospital (YGH) – 
the only one in 
the country to 
offer 
chemotherapy 
M T C P 
13 July -
12 Aug 
2010 
Patients aged ≥18 yrs with 
primary invasive BC (98% 
with histological 
confirmation) and who 
received chemotherapy; 
96% female 
Me: 46  
 
Ra: 29-75 
n/a n/a n/a n/a n/a 20 
T
o
u
r
e
,
 
2
0
1
3
 
(
2
2
)
 Cote 
d'Ivoire 
(n=350) 
University 
Hospital of 
Treichville, 
Abidjan 
M T  C Re Jan 2008 - Dec 2011 
Patients with a 
histologically-confirmed 
adenocarcinoma of the 
breast 
Me: 42  
 
Ra: 18-
81 
Breast lump: 6%; 
Inflammation: 
54%; Ulcer: 18% 
Nipple blood 
discharge: 8% 
Metastases: 14% 
III: 76.3%; 
IV: 14.3% n/a n/a 
Adeno-
carcinoma: 
100% 
19 
 
QUANTITATIVE AND QUALITATIVE STUDIES (n=2)  
D
y
e
,
 
2
0
1
0
 
(
2
3
)
 
Ethiopia 
(n=69; 
98.1% 
females) 
Tikur Anbessa 
Hospital (TAH) M T C P 
2008  
(1 mth 
only) 
Randomly selected female 
and male BC patients seen 
at TAH over the span of 1 
mth (similar characteristics 
to the total population). 
Patients or their families 
were interviewed. 
Me: 44.5 n/a n/a n/a n/a n/a 10 
L
y
,
 
2
0
0
2
 
(
2
1
)
 
Mali 
(n=44; 43 
females) 
Hôpital du 
Point-G, 
Bamako 
M T C P 
15 Sept 
1998 - 15 
Aug 2000 
Newly-diagnosed and 
histologically-confirmed 
BC patients (male and 
female) seen at the 
haematology / oncology 
service 
Me (SD): 
46 +19.5 
 
Ra: 25-80 
Breast lump: 39%; 
Breast pain: 39%;  
Pruritus (itching): 
12% 
Nipple blood 
discharge: 6.8% 
Ulcer: 4.5% 
III: 40.9%; 
IV: 45.5% n/a n/a n/a 7 
 
QUALITATIVE STUDIES (n=3) 
 
E
k
o
r
t
a
r
l
,
 
2
0
0
7
 
(
1
1
)
 
Cameroon 
(n=9 BC 
cases; 11 
subjects 
with other 
types of 
cancer) 
Yaounde 
General 
Hospital  
M T O P n/a 
Cancer patients  who 
presented with advanced 
disease or who re-appeared 
at an advanced stage  after 
having abandoned treatment 
at the Oncology Division 
Ra: 34-63 n/a Advanced BC: 100% n/a n/a n/a n/a 
M
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a
 Population-based: urban (U), rural (R), mixed (M) area, or not reported (n/a)  
b
 Primary (P), secondary (S) or tertiary (T) hospital/clinic 
c
 Opportunistic (O) or consecutive (C) sample of patients  
d
 Patients recruited prospectively (P) or retrospectively (Re)  
e
 Stages III-IV (note: T2 can be staged as IIIA) 
 
BC: breast cancer; BSE: breast self-examination; CBE: clinical breast examination; IDC: invasive ductal carcinoma; IQR: inter-quartile range; LABC: Locally advanced breast cancer; Md: median; Me: mean; 
mths: months; n/a: not reported in the original publication; Ra: range; SD: standard deviation; wks: weeks; yrs: years 
 
 
  
M
b
u
k
a
-
O
n
g
o
n
a
,
 
2
0
1
2
 
(
1
2
)
 
Botswana 
(n=11) 
Princess Marina 
Hospital (PMH), 
Gaborone (the 
only hospital in 
the country with 
oncology 
services) 
M T O P 2007 
Inclusion: All female adult 
BC patients seen and 
managed at PMH.  
Exclusions: aged <18 yrs; 
too ill or mentally 
incapacitated 
Me: 54 
 
Ra: 37-76 
Most common: 
painless lump; 
second most 
common: bloody 
nipple discharge 
Majority 
stage III n/a n/a n/a n/a 
P
r
u
i
t
t
,
2
0
1
5
 
(
2
0
)
 Nigeria 
(n=31) 
University 
College Hospital 
Ibadan 
M T C P July 2011 
All female BC patients seen 
in the radiotherapy and 
surgery clinics, aged ≥18 
yrs, regardless of ethnicity, 
language or stage.  
Md: 51 
 
Ra: 28-80 
n/a n/a n/a n/a n/a n/a 
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Table 2. Time from recognition of potential symptoms of breast cancer to presentation to the first health care provider, diagnosis and start of treatment, and number of health care providers 
visited  
Author, year [ref no] Country (sample size) 
Time from: No. health care providers 
(HPC) visited prior to visit 
to the one where diagnosis 
was made 
Symptom recognition to 
presentation Presentation to diagnosis Diagnosis to start of treatment 
North Africa 
Ahmed, 2014 (14)a Sudan (n=141) Md: 12 mths; Ra: 2-108 mths n/a n/a 
Aloulou, 2015 (17) Morocco (n=130) Me: 8.47 mths;  > 6 mths: 63.1% n/a n/a 
Benbakhta, 2015 (18) Morocco (n=200) 
Md: 65 days (=2.17 mths);  
IQR: 31-121 days; Ra: 3-579 days 
Md: 20 days (=0.67 mths);  
IQR: 10-40 days; Ra: 1-433 days 
Md: 25 days (=0.83 mths);  
IQR: 9-42 days; Ra: 0-368 days 
n/a Md: 50 days (=1.67 mths);  
IQR: 29, 77 days; Ra: 5-535 days 
Md: 120 days (4.0 mths);  
IQR: 81-202 days; Ra: 14-860 days 
El-Shinawi, 2013 (33) Morocco (n=45) 
<1 mth: 46.7% 
1- <6 mths: 37.8% 
6 - <12 mths: 0%  
>12 mths: 15.6% 
n/a n/a n/a 
Ermiah, 2012 (24) Libya (n=200) 
Md: 4 mths (max. 24) 
<3 mths: 46%  
3-6 mths: 14%  
>6 mths: 40% 
Md: < 1 mth 
<1 mth: 84.5% 
1-6 mths: 4.5% 
>6 mths: 11.0% 
n/a n/a 
Md: 7.5 mths (max. 25 mths) 
<3 mths: 30% 
3-6 mths: 14%  
>6 mths: 56% 
Landolsi, 2010 (13)a Tunisia (n=160) Mean: 11.6 mths; Md: 8 mths n/a n/a 
Mousa, 2011 (26) Egypt (n=163) 
Me: 6.2 mths; Md: 2.3 mths Presentation to arrival at TCC: 
Me: 6.8 wks; Md: 2.5 wks n/a 
Me: 1.5 Range: 0-4  
(does not mention traditional 
or spiritual healers) 
Stapleton, 2011 (9) Egypt (n=343) Md: <1 mth n/a n/a n/a 
Sub-Saharan Africa 
Clegg-Lamptey, 2009 (28) Ghana (n=66) 
Me: 46 wks (=10.7 mths) 
Md: 34 wks (=7.9 mths) 
Ra: 1 wk, 5 yrs 
n/a Previous medical 
consultation: 39.4% 
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Ezeome, 2010 (25) Nigeria (n=162) 
<1 mth: 26.4% 
1 - 3 mths: 28.3% 
>3 - 6 mths: 17.6% 
>6 mths: 27.7% 
<1 mth: 17% 
1 - 3 mths: 10.6% 
>3 - 6 mths:16% 
>6 mths: 56.4% 
n/a 
<1 mth: 5.6% 
1 - 3 mths: 4.3% 
>3 – 6 mths: 17.3% 
>6 mths: 72.8% 
Ibrahim, 2012 (45) Nigeria (n=201) 
Me (SD): 12.12 (5.18) mths 
Ra: 1 wk – 96 mths 
<1 mth: 4.5% 
1-3 mths: 13.9% 
>3 – 6 mths: 32.8% 
>6-12 mths: 30.8% 
>12 mths: 17.9% 
n/a n/a n/a 
Marcus, 2013 (15)a South Africa (n=103) 
< 3 mths: 17.5% 
3-6 mths: 30.1% 
>6 mths: 52.4% 
n/a n/a n/a 
Otieno, 2010 (16)a Kenya (n=166; 98.8% females) 
From first symptoms to presentation at Kenyatta National Hospital  
(late stage only) 
< 30 days: 6.62% 
31 – 90 days: 20.4% 
> 90 days: 73.08% 
n/a n/a 
Pace, 2015 (19) Rwanda (n=144) 
Md: 5 mths (IQR: 1-13) Md: 5 mths (IQR: 2-14) 
n/a 
< 5 HCP visits : 44% 
> 5 HCP visits: 56% 
(does not mention traditional 
or spiritual healers) 
Md: 15 mths (IQR: 8 – 32)  
Price, 2012 (27) Cameroon (n=50) n/a 
>3 mths: 42% 
>6 mths: 32% n/a 
Consulted ≥4 HCP: 46% 
(including traditional and 
spiritual healers) >6 mths: 60% 
Toure, 2013 (22) Cote d'Ivoire (n=350) 
< 6 mths: 9.1% 
6-10 mths: 12% 
10-14 mths: 78.9% 
Weighted mean: 10.7 mths 
n/a n/a 
 
QUANTITATIVE and QUALITATIVE STUDIES 
Dye, 2010 (23) Ethiopia (n=69; 98.1% females) n/a n/a n/a 
>2 HCP visits: 73.2% 
(including traditional or 
spiritual healers) 
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Ly, 2002 (21) Mali (n=44; 43 females) 
1 - 12 wks (=2.8 mths): 63.6% 
13 (=3.0 mths) – 48 wks (=11.2 
mths): 36.4% 
Weighted mean: 3.4 mths 
n/a 
n/a 
>3 HCP: 50% 
(only conventional HCP 
included) 
From symptoms to first appointment at the study (diagnostic) hospital: 
Ra: 8 wks (=1.87 mths) – 72 wks (=16.8 mths)  
 
QUALITATIVE STUDIES 
Ekortarl, 2007 (11) 
Cameroon (n=9 BC cases; 
11 subjects with other 
types of cancer) 
n/a n/a n/a n/a 
Mbuka-Ongona, 2012 (12) Botswana (n=11) Time from first symptom to presentation at study hospital (PMH): Me: 3 yrs; Ra: 1 - 10 yrs n/a n/a 
Pruitt, 2015 (20) Nigeria (n=31) n/a n/a n/a 
 
a Study recruited only patients with advanced breast cancer (see Table 1) 
BC: breast cancer; CI: confidence interval; HCP: health care provider; IQR: inter-quartile range; Md: median; Me: mean; mths: months; n/a: not reported in the original publication; Ra: range; TCC: Tanca Cancer 
Center; wks: weeks; yrs: years 
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  Appendix A: Example of the search string used in MEDLINE 
1 (breast OR mammary) ADJ3 (neoplasm* OR cancer* OR tumo?r* OR carcinoma) 
2 exp Breast Neoplasms 
 
3 1 OR 2 
 
4 (delay* OR late OR poor) ADJ1 (presentation OR attendance OR diagnosis OR stage OR detection OR 
prognosis)  
5 exp Delayed Diagnosis 
6 exp Prognosis 
7 exp Early Diagnosis 
 
8 4 OR 5 OR 6 OR 7 
 
9 (determinant* OR factor* OR reason* OR barrier* OR attitude* OR belie* OR awareness OR knowledge 
OR fear* OR cultur* OR perception*)  
 
10 (uptake OR utilization OR access OR accept* OR intent* OR distance OR transport* visit* OR presentation*) 
ADJ3 (health care centre OR hospital OR clinic OR health service OR doctor OR physician OR mammogram* 
OR screening OR exam*) 
 
11 exp “Behavior and Behavior Mechanisms” 
12 exp Attitude to Health 
13 exp Socioeconomic Factors 
14 exp Health Status Disparities 
15 exp Communication Barriers 
 
16 OR/9-15  
 
17 Africa OR Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cameroon OR 
Cape Verde OR Central African Republic OR Chad OR Democratic Republic of the Congo OR Djibouti OR 
Egypt OR Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea-Bissau OR 
Guinea OR Ivory Coast OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR 
Mauritania OR Mauritius OR Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Republic of 
Congo OR Rwanda OR Senegal OR Sierra Leone OR Somalia OR South Africa OR South Sudan OR Sudan OR 
Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR Zambia OR Zimbabwe 
 
18 exp Africa 
19 17 OR 18  
20 3 AND 8 AND 16 AND 19 
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Appendix B: Quality assessment of the eligible papers 
 
The quality of the articles included in the review was assessed by developing a standardized quality assessment 
form which included parameters on three main domains: (1) Selection bias: study design (score 0 if unclear, 1 if 
retrospective case series, 2 if prospective study); study population (score 0 if unclear, 1 if opportunistic hospital-
based study, 2 if consecutive hospital-based study, 3 if population-based study); restricted to late stage/advanced 
disease (score 0 if unclear, 1 if yes, 3 if no); participation rate (score 0 if unclear, 1 if <70%, 2 if ≥70%). (2) 
Information bias: source of the information (i) for patient-mediated factors (score 0 if unclear or n/a (not 
applicable), 1 if medical records, 2 if proxy (relative), 3 if patient); (ii) for health service-mediated factors (score 
0 if unclear or n/a, 1 if proxy (relative), 2 if patient, 3 if medical records); timing of information collection (score 
0 if unclear or n/a, 1 if after patient was aware of her breast cancer diagnosis, 2 if around the time of her 
diagnosis, 3 if before her diagnosis); potential of observer/interviewer bias (score 0 if unclear, 1 if likely, 2 if 
unlikely as information was validated against medical records or a previously-validated questionnaire was used). 
(3) Analytical methods including dealing with potential confounders: definition of delays in presentation, 
diagnosis and/or treatment (score 0 if not given, 1 if given but unclear or stage used as a proxy, 2 if clear); 
distinction between patients’ and health system’s related factors (score 0 if not given, 1 if focus only on one of 
these, 2 if given but unclear, 3 if clear); statistical methods (score 0 if not properly described, 1 if only 
descriptive, 2 if analytical or in-depth); adjustment for potential confounders (score 0 if n/a, 1 if only crude 
estimates given, 2 if adjusted). The overall quality score of a paper was expressed as the sum of its parameter-
specific scores, which could range from 0 (lowest) to 30 (highest). The higher the score, the higher the 
methodological quality of the paper and, hence, the lower the score, the more likely its findings might have been 
affected by biases. 
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Appendix C: Factors associated with delayed presentation and delayed diagnosis or start of treatment of breast cancer in Africa: summary of the findings reported by the 
studies included in the review.  
Author, 
Year 
[ref no] 
(country) 
Factors associated with delay between symptoms recognition and first visit to a 
health care provider (HCP) 
Factors associated with delay between first visit to a health care provider 
(HCP) 
and breast cancer (BC) diagnosis or start of treatment 
Crude Adjusted Crude Adjusted 
North Africa 
Ahmed, 
2014 (14)a 
(Sudan)  
Factors associated with late presentation in patients with LABC (%) 
 
Lack of education: 39.5% 
Financial aspects: 28.6% 
Use of traditional medicine: 13.8% 
Limited access to medical care: 9% 
Ignorance: 6.9% 
Fear of being a burden to relatives: 2.7% 
 
 
 
 
n/a 
Aloulou, 
2015 (17) 
(Morocco) 
Reasons for delays from symptoms recognition to diagnosis: 
Fear of cancer and/or treatment: 4%; 
Financial problems: 40%; 
Tried traditional treatments: 20% 
Health services: 
Distance from health centre: 23%; 
Wrong diagnosis: 6%; 
Inadequate medical care: 7% 
Benbakhta, 
2015 (18) 
(Morocco) 
Delay from symptoms recognition to 
presentation >2.2 mths: OR (95% CI) 
 
Socio-economic: 
Aged >65 vs. <45 yrs: 1.68 (0.64, 4.38) 
Rural vs. urban area of residence: 4.62 
(2.24, 9.52) 
Illiteracy vs. secondary/university: 4.56 
Delay from symptoms recognition to 
presentation >2.2 mths: OR* (95% 
CI) 
 
Socio-economic: 
Rural vs. urban  area of residence: 3.00 
(1.24, 7.23) 
Illiteracy vs. secondary/university: 4.90 
Delay between presentation and start of 
treatment >1.7 mths: OR (95% CI) 
 
Socio-economic: 
Aged >65 vs. <45 yrs: 1.94 (1.36, 2.40) 
Rural vs. urban area of residence: 2.10 
(1.18, 4.40) 
Illiteracy vs. secondary/university: 2.70 
Delay between presentation and start 
of treatment >1.7 mths: OR* (95% 
CI) 
 
Socio-economic: 
Aged >65 vs. <45 yrs: 2.51 (1.50, 
11.42) 
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(2.26, 9.18) 
Employed vs. housewife: 0.23 (0.13, 0.57) 
Low vs. mid socioeconomic level: 8.55 
(3.16, 23.17) 
>5 people in household: 2.05 (1.14, 3.69) 
 
BC awareness: 
No knowledge vs. knowledge of BSE: 
17.88 (8.74, 36.56) 
Positive vs. negative family history: 2.51 
(1.23, 5.13) 
Type of symptoms: 
Presence of typical vs. atypical symptoms: 
0.75 (0.33, 1.67) 
 
Health services related: 
Distance from HCP of presentation  
≥100vs <100 kms kms: 8.62 (1.01, 67.14) 
(2.50, 6.30) 
Employed vs. housewife: 0.1 (0.03, 
0.47) 
Low vs. mid socioeconomic level: 7.60 
(2.24, 25.77) 
 
 
 
BC awareness: 
No knowledge vs. knowledge of BSE: 
11.51 (5.18, 25.57) 
Negative vs. positive family history: 
2.11 (1.10, 4.16) 
 
*Mutually-adjusted 
(1.38, 5.27) 
Low vs. mid socioeconomic level: 2.61 
(1.20, 23.17) 
 
 
 
Health services: 
Distance to HCP of diagnosis >100 vs. 
<100 kms: 2.46 (1.26, 5.20) 
≥3 vs <3 consultations before diagnostic 
one: 11.44 (4.83, 27.08)  
 
 
 
 
Illiteracy vs. secondary/university: 1.40 
(1.12, 6.50) 
Low vs. mid socioeconomic level: 2.59 
(1.04, 6.50) 
 
 
 
Health services: 
Distance to HCP of diagnosis >100 vs. 
100 kms: 2.58 (1.12, 3.56) 
>3  vs <3 consultations before 
diagnostic one: 11.27 (4.12, 28.34) 
 
*Mutually-adjusted 
El-Shinawi, 
2013 (33) 
(Egypt) 
Delay from symptoms recognition to 
presentation to a HCP 
 
BC awareness: 
Higher awareness of BSE associated with 
less delay in seeking medical advice 
(2.9+2.3 months) relative to low awareness 
(15.5+22.6 months)  (P=0.04) 
n/a n/a n/a 
Ermiah, 
2012 (24) 
(Lybia) 
Delay from symptom recognition to diagnosis >3 mths 
 
Socio-economic:  
Aged ≥50 vs <50 yrs: 64% vs 51% (P=0.033) 
Single vs married: 52% vs 56% (P=0.6) 
Housewife vs employed: 61% vs 48% (P=0.09) 
Illiteracy vs literacy: 69% vs 38% (P=0.009) 
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Reproductive: 
Post- vs. pre-menopausal: 64% vs 50% (P=0.05) 
No vs. breastfeeding: 38% vs 58.6% (P=0.09) 
OC use >5 yrs vs. <5yrs or no use: 86% vs 53% (P=0.04) 
 
BC awareness:  
Positive vs negative family history: 45% vs 57% (P=0.3) 
Positive vs. negative history of benign breast disease: 73% vs. 52% (P=0.03) 
Knowledge of BSE vs no knowledge: 0% vs 58% (P<0.0001) 
 
Type of symptoms: 
Initial symptom being a lump vs being other symptoms: 41% vs 86% (P<0.0001) 
Landolsi, 
2010 (13)a 
(Tunisia) 
Delay from symptoms recognition to presentation at study setting, i.e. to diagnosis  
 
93% delay related to personal reasons: 
Not aware of disease: 35% 
Not having practiced BSE: 23.5% 
Fear of cancer and/or treatment: 14% 
Financial problems: 14% 
Others: 13.5% 
24% delay related to health services: 
Wrong reassurance: 47.5% 
Misdiagnosis: 18% 
Mousa, 
2011 (26) 
(Egypt) 
Delay from symptoms recognition to 
first medical consultation >3 mths: OR 
(95% CI) 
 
Socio-economic: 
Aged ≥50 vs <50 yrs: 1.1; 95%CI: 0.6, 2.1 
Urban vs rural residence: 1.3; 95%CI: 0.7, 
2.6 
≥Bachelor vs <bachelor education:  
Delay from symptoms recognition to 
first medical consultation >3 mths: 
OR* (95% CI) 
 
Socio-economic: 
Aged ≥50 vs <50 yrs: 0.9 (0.4, 1.9) 
Urban vs. rural residence: 1.4 (0.7, 2.9) 
≥Bachelor vs. <bachelor education:  
0.6 (0.3, 1.2) 
Delay from first medical consultation to 
arrival at TTC >2 wks: OR (95% CI) 
 
Socio-economic: 
Aged ≥50 vs <50 yrs: 0.6 (0.3, 1.2) 
Urban vs. rural residence: 0.8 (0.4, 1.5) 
≥Bachelor vs. <bachelor education:  
1.2 (0.7, 2.3) 
 
Delay from first medical consultation 
to arrival at TTC >2 wks: OR* (95% 
CI) 
 
Socio-economic: 
Aged ≥50 vs <50 yrs: 0.6 (0.3, 1.4) 
Urban vs. rural residence: 1.1 (0.5, 2.3) 
≥Bachelor vs. <bachelor education:  
1.3 (0.5, 2.9) 
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0.6 (0.3, 1.2) 
 
Type of symptoms: 
Breast mass vs. other first symptom:  
2.1 (0.9, 4.8)  
 
Type of symptoms: 
Breast mass vs. other first symptom:  
2.1 (0.9, 4.8)  
 
*Adjusted for age, residential status 
and education 
 
 
Type of symptoms: 
Breast mass vs. other first symptom: 
0.8 (0.4, 1.8) 
 
Health services-related: 
First health care provider vs TCC:  
Primary care: 11.0 (2.9, 41.7) 
Gynaecologist: 9.0 (1.6, 52.3) 
Medical oncologist: 5.6 (1.0, 30.9) 
General surgeon: 5.5 (1.7, 18.0) 
Surgical oncologist: 3.0 (0.7, 13.4) 
Other: 12.0 (2.2, 66.5) 
 
Navigation pathway vs directly to TCC:   
General surgeon  Surgical oncologist 
TCC: 29.3 (4.6, 184.4) 
General surgeon  Medical oncologist 
TCC: 6.0 (0.9, 38.1) 
Primary care Others TCC: 19.5 (3.7, 
102.4) 
 
 
 
Type of symptoms: 
Breast mass vs. other first symptom: 
1.3 (0.6, 3.1) 
 
Health services-related:  
First health care provider vs TCC:  
Primary care: 12.2 (2.9, 51.0) 
Gynaecologist: 8.6 (1.4, 53.4) 
Medical oncologist: 8.3 (1.3, 55.0) 
General surgeon: 7.6 (2.1, 27.6) 
Surgical oncologist: 3.4 (0.7, 16.0) 
Other: 11.0 (1.9, 63.3) 
 
Navigation pathway vs directly to 
TCC:   
General surgeon  Surgical 
oncologist TCC: 35.4 (5.3, 237.5) 
General surgeon  Medical 
oncologist TCC: 8.1 (1.0, 62.2) 
Primary care Others  TCC: 23.2 
(4.0, 134.5) 
 
*Adjusted for age, residential status, 
education level, tumour stage, and first 
symptom 
Stapleton, 
2011 (9) 
(Egypt) 
Late vs early stage at diagnosis: Mutually-adjusted OR (95%CI) 
 
>33 wks vs. ≤33 delay in seeking treatment: 1.57 (0.76, 3.23) 
  
Financial and other constraints 
Social, financial and time constrains vs. no delay: 1.72 (0.86, 3.46) 
Type of symptoms: 
No pain vs. no delay: 2.68 (1.18, 6.08) 
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BC awareness: 
Knowledge of BSE vs. no knowledge: 0.24 (0.06, 0.94) 
Previous CBE vs. no previous CBE: 1.00 (0.28, 3.62) 
Previous mammogram vs. no previous mammogram: 2.17 (0.48, 9.72) 
 
Health services related: 
Site of treatment NCI-Cairo vs. TCC: 5.05 (1.30, 19.70) 
Visited vs. not visited a second provider: 0.72 (0.30, 1.74) 
First diagnosed vs. not first diagnosed as BC: 0.99 (0.52, 1.89) 
Referral vs. no referral: 1.10 (0.57, 2.12) 
Treated in a hospital vs present facility: 0.80 (0.43, 1.48) 
Travel time to facility >1 hr vs. ≤1 hr: 1.64 (0.96, 2.79) 
Sub-Saharan Africa  
Clegg-
Lamptey, 
2009 (28) 
(Ghana) 
Reasons for delay from symptoms recognition to presentation at the study hospital where diagnosis was made (%) 
 
Lack of BC awareness: 28.8%; 
Fear of diagnosis or mastectomy: 34.8%; 
Tried traditional/alternative treatments: 19.7%; 
Tried spiritual cures: 19.7%; 
Financial problems: 18.2%; 
Lack of knowledge of BSE: 57.6% 
Other: 4.5% 
 
Health services related: 
Previous medical consultation: 39.4%; 
Previous hospital consultations at a different hospital: 72.7%, with diagnosis made in only 52% of these. 
Ezeome, 
2010 (25) 
(Nigeria) 
Reasons for delay between symptoms 
recognition and visit to first HCP 
 
Symptom(s) not serious/hoping they will 
resolve: 27.8%; 
Lack of BC awareness: 23.3%; 
Tried traditional/ spiritual treatments: 
n/a 
Reasons for delay between symptoms 
recognition and start of BC treatment 
 
Patient-related 
Lack of BC awareness: 25.3% 
Finance: 16.9% 
Thought it was harmless/will disappear: 
n/a 
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12.6%; 
Financial problems: 13.9%; 
Painless: 12%; 
Fear/refusal of mastectomy: 5.6%; 
Family/social problems: 5.6%; 
Though it was pregnancy/lactation effect: 
3.2% 
Discouraged by friends/relatives: 3.2% 
Others:  15.7% 
15.4% 
Fear/refused surgery/mastectomy: 9.2% 
Painless/not disturbing her: 6.9% 
Delayed by family/social problems: 6.9% 
Traditional/spiritual treatments: 5.4% 
Discouraged by friends/relatives: 5.4% 
 
Health Care Provider-related: 
Delayed referrals or non-referrals: 17.8%; 
Wrong advice and false reassurance by 
health professionals: 11.5%; 
Delayed histology report: 6.2%; 
No histology after biopsy: 5.4%; 
Industrial actions: 4.6% 
Ibrahim, 
2012 (45) 
(Nigeria) 
Delay from symptoms recognition to 
first medical consultation >3 mths 
 
Reasons given: 
Lack of BC awareness: 34.1%;  
Belief in spiritual healing: 32.3%;  
Fear of mastectomy: 29.3%;  
Belief in herbal treatment: 22%;  
Belief in alternative therapy: 7.3%;  
Lack of funds: 3%;  
Reassurance by non-medical health 
worker: 3% 
 
Crude analysis: 
Being single: OR=2.05, 95%CI: 0.25, 
16.8;  
Primary level of education: OR=3.06, 
95%CI: 0.96, 9.73;  
Negative history of benign breast disease: 
OR=1.65, 95%CI: 0.76, 3.59  
Delay from symptoms recognition to 
first medical consultation >3 mths 
 
 
 
 
 
“In the multivariate analysis, being pre-
menopausal (OR=1.86; 95% CI: 0.38, 
9.4) was the additional factor 
associated with increased risk of late 
presentation” (sic)  
n/a n/a 
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Marcus, 
2013 (15)a 
(South 
Africa)  
Delay from first symptoms to 
presentation >6 mths vs 3-6 mths: OR 
(95% CI) 
 
Socio-economic: 
Age (vs 34-45 (sic)):  
  45-54: 0.15 
  55-64: 0.18 
  65-83: 0.77  
Education (vs. none):  
  Primary: 0.41 
  Secondary or higher: 0.18 
Employed vs unemployed: 0.26 
Married vs single/divorced/widowed: 0.31 
 
BC awareness: 
Previous cancer diagnosis: 0 
 
 Delay from first symptoms to 
presentation >6 mths vs 3-6 mths: 
Adjusted* OR (95% CI) 
 
Socio-economic: 
Age (vs 34-45 (sic)):  
   45-54: 2.05 
   55-64: 2.55 (P<0.05);  
   65-83: 2.28 
Education (vs. none):  
   Primary: 0.27 
   Secondary or higher: 1.56 
Employed vs unemployed: 0.63 
Married vs single/divorced/widowed: 
0.84 
 
BC awareness: 
Previous cancer diagnosis: 22.13 
(P<0.01) 
 
*for all variables in the model 
n/a n/a 
Otieno, 
2010 (16)a 
(Kenya) 
Reasons for delays from first symptoms to presentation at diagnostic hospital, i.e. to diagnosis    
 
Lack of BC awareness: 7.8%; 
Painless symptom(s): 23.5%; 
Fear of cancer: 19.9%; 
Symptoms considered benign by health professionals: 24.1% 
Tried traditional treatments: 9.6% 
Others: 15.1% 
Pace, 2015 
(19) 
(Rwanda) 
Reasons for delay between first 
symptoms to first visit to a HCP (%) 
 
 
Reasons for delay between first 
symptoms to first visit to a HCP:   
OR* (95% CI) for delay >6 vs <6 
mths  
Reasons for delay between first visit to 
a HCP and date of pathology report 
confirming BC (%) 
 
Reasons for delay between first visit 
to a HCP and date of pathology 
report confirming BC 
OR* (95% CI) for delay >6vs. 6 mths  
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Did not think it was a problem at first: 
76%; 
Thought it would go away: 63%; 
Visited traditional healer first: 21%; 
Thought treatment was too expensive: 
14% 
Too busy at home or job: 7%;  
Fear of cancer: 6%  
Afraid of treatment & mastectomy: 5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Socio-economic: 
Age (yrs) vs. <40 yrs:  
   40-49: 2.26 (0.69, 7.43); 
    50-59: 1.22 (0.36, 4.11);  
   >60: 2.30 (0.60, 8.74) 
Married vs. unmarried: 1.11 (0.51, 
2.48) 
No education/primary school vs 
secondary/university: 4.88 (1.72, 
13.88) 
 
Reproductive: 
Breastfeeding (yes vs. no): 2.09 (0.44, 
9.87) 
 
BC awareness: 
BC family history (yes vs no): 0.53 
(0.14, 2.04) 
Ever done BSE (yes vs no): 0.73 (0.31, 
1.74) 
Ever heard of BC (yes vs no): 1.86 
(0.69, 5.00) 
 
Type of symptoms & co-morbidities: 
Breast pain as initial symptom (yes vs 
no): 0.57 (0.25, 1.30)   
HIV or other comorbidities (yes vs 
no/unknown): 1.15 (0.43, 3.07) 
 
Alternative treatments: 
Saw traditional healer first: 4.26 (1.56, 
11.60) 
 
 
 
Non-referral from another health care 
centre: 69% 
Did not know this cancer existed: 30% 
Did transfer form from another health 
facility: 27% 
Too expensive to travel from home to 
hospital: 21% 
Told by a health care provider there was 
no cure: 3% 
Hospital to far to travel to: 2%  
 
 
 
 
 
 
 
 
 
Socio-economic: 
Age (yrs) vs. <40 yrs:  
   40-49: 0.57 (0.20, 1.68); 
   50-59: 0.85 (0.28, 2.62);  
   >60: 0.64 (0.18, 2.24) 
Married vs. unmarried: 1.11 (0.51, 
2.41) 
No education/primary school vs 
secondary/university: 1.19 (0.48, 2.97) 
 
Reproductive: 
Breastfeeding (yes vs. no): 0.81 (0.15, 
4.30) 
 
BC awareness: 
BC family history (yes vs no): 0.60 
(0.15, 2.34) 
Ever done BSE (yes vs no): 1.15 (0.50, 
2.65) 
Ever heard of BC (yes vs no): 1.19 
(0.45, 3.10) 
 
Type of symptoms & co-morbidities: 
Breast pain as initial symptom (yes vs 
no): 1.15 (0.52, 2.55)   
HIV or other comorbidities (yes vs 
no/unknown): 0.84 (0.32, 2.17) 
 
Health services related: 
Travel time to HCP (>2 vs ≤2 hrs): 
1.26 (0.46, 3.42) 
Regular CHW visits (yes vs no): 1.14 
(0.50, 2.58) 
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Health services related:  
Travel time to HCP (>2 vs ≤2 hrs): 
0.96 (0.36, 2.57) 
Regular CHW visits (yes vs no): 1.51 
(0.66, 3.46) 
 
 
* Mutually-adjusted for all variables in 
the model 
No. visits to other healthcare facilities 
prior to diagnosis (<5 vs >5): 2.69 
(1.24, 5.84) 
Referred by (vs health centre): 
   District hospital: 0.51 (0.09, 2.78) 
   Private hospital: 0.36 (0.06, 2.09) 
   Unknown: 0.49 (0.07, 3.45) 
 
* Mutually-adjusted for all variables in 
the model 
Price, 2012 
(27) 
(Cameroon) 
Financial problems: 16% 
Spent >$10 on 1-way transportation: 42% 
Travelled >4h to hospital: 46% 
n/a 
Toure, 
2013 (22) 
(Côte 
d’Ivoire) 
Reasons for delay between symptoms recognition and date of histological confirmation 
Crude OR (95% CI) for delay >6 mths  
 
Initial symptom (vs. nodule) 
  Inflammation: 23.6 (7.5, 74.0) 
  Ulcer: 18.1 (4.3, 76.9) 
  Nipple discharge: 1.9 (0.6, 6.2) 
  Metastases: 13.9 (3.3, 59.3) 
 
Self-reported reason for delay (vs. having financial problems) 
  Traditional medicine: 0.5, (0.2, 1.2) 
  Fear of cancer: 0.4, (0.1, 2.3) 
  Misdiagnosis: 1.8 (0.2, 15.3) 
  Inadequate medical care: 1.1 (0.2, 5.4) 
 
Monthly income in euros (vs. none): 
<91.46: 1.4 (0.5, 3.6) 
91.46 – 182.8: 0.8 (0.3, 2.1) 
Mutually-adjusted OR (95% CI) for delay >6 mths  
(having financial problems taken as the reference category) 
 
Self-reported reason for delay (vs. having financial problems) 
  Traditional medicine: 0.7, (0.7, 3.2) 
  Fear of cancer: 1.2, (0.0, 12.3) 
  Misdiagnosis: 3.0 (0.3, 5.7) 
  Inadequate medical care: 0.6 (0.1, 17.4) 
 
Monthly income in euros (vs. none): 
  <91.46: 0.3 (0.0, 1.7) 
  91.46 – 182.8: 4.4 (0.2, 91.2) 
  182.9 – 274.4: 12.7 (0.4, 376.6) 
   >274.4: 47.8 (0.7, 3.103 (sic)) 
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182.9 – 274.4: 0.8 (0.3, 2.3) 
> 274.4: 3.2 (0.4, 25.9) 
 
QUANTITATIVE & QUALITATIVE STUDIES 
Dye, 2010 
(23) 
(Ethiopia) 
Reasons for delays between symptom recognition and presentation at diagnostic centre (TA) 
 
Lack of BC awareness 
 
Health services: 
High travel distance 
Too expensive 
>3 HCP visits: 73.2% 
First HCP: % of patients (Me ± SE number of care nodes visited including study setting (TAH)): 
Primary care: 53.7% (3.3 ± 1.8) 
Traditional healer: 16.4% (3.8 ± 0.26) 
Local/regional hospital: 16.4% (2.3 ± 0.19) 
Private hospital: 9% (2.8 ± 0.48) 
TAH: 4.5% 
Ly, 2002 
(21) 
(Mali) 
Reasons for delays between symptom recognition and presentation at first HCP 
Symptom(s) not serious: 82%; 
Caused by witchcraft: 14% 
n/a 
 
QUALITATIVE STUDIES 
Ekortarl, 
2007 (11) 
(Cameroon) 
Reasons for delays between symptom recognition and presentation at first HCP 
 
Ignorance and beliefs 
Fears 
Financial problems 
Inadequate diagnosis by general doctors 
 
Mbuka-
Ongona, 
2012 (12) 
(Botswana) 
Reasons for delays between symptom recognition and visit to diagnostic centre 
 
Lack of BC awareness Misinterpretation of signs 
Infrequently BSE 
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a Study recruited only patients with advanced breast cancer (see Table 1) 
BC: breast cancer; BSE: breast self-examination; CBE: clinical breast examination; CHW: community health worker; CI: confidence interval; HCP: health care provider; 
HIV: Human immunodeficiency virus; IQR: inter-quartile range; km: kilometres; LABC: Locally advanced breast cancer; Md: mean; Me: mean; mths: months; n/a: not 
reported in the original publication; OC: oral contraceptives; OR: odds ratio; Ra: range; SE: standard error; TAH: Tikur Anbessa Hospital; TCC: Tanca Cancer Center; wks: 
weeks; yrs: years 
 
Fear diagnosis and death 
Influence of traditional healers 
 
Health services: 
Poor clinical practices of health workers 
 
Overemphasis on HIV infection 
Long travel distance to hospital 
Pruitt, 2015 
(20) 
(Nigeria) 
Reasons for delays between symptom recognition and first visit to a HCP 
 
Lack of BC awareness 
Symptom(s) not serious 
Tried traditional & spiritual treatments 
Reasons for delays between presentation and diagnosis & treatment 
 
Inappropriate medical care given 
Delays in getting diagnostic confirmation or treatment 
Return to traditional care 
Denial 
Fear of surgery 
Strikes by hospital staff 
Treatment costs  
